A retrospective chart review of pediatric patients with MS at a tertiary treatment center showed how the center’s first ...

The investigational therapy fenebrutinib was as effective as Ocrevus for reducing disability progression in people with PPMS, a trial showed.

In a study, blocking the immune system complement protein C3 was shown to reduce MS disease severity in older mice but not in ...

The Breakthrough Prize has announced its 2025 Laureates in Life Sciences, Fundamental Physics, and Mathematics. Among them are Professors Alberto Ascherio from Harvard University and Stephen Hauser ...

Monoclonal antibody DMTs, especially anti-CD20 therapies, effectively prevent relapses but have limited impact on progressive MS. Progressive MS involves compartmentalized CNS inflammation, with ...

HOUSTON and WALTHAM, Mass., April 17, 2025 /PRNewswire/ -- Biostate AI, a leading innovator in artificial intelligence for RNA sequencing, today announced a strategic partnership with the Accelerated ...

Multiple sclerosis (MS) is a chronic disease of the central nervous system that causes disruptions in the flow of information within the brain and between the brain and body, eventually causing ...

Tyruko ® (natalizumab-sztn), a biosimilar to Tysabri ® (natalizumab), has been made available by Sandoz, according to developer Polpharma Biologics. Tyruko is an integrin receptor antagonist approved ...

The results reinforce the need for individualized, biology-driven therapeutic decisions in patients with MS. SAN DIEGO – Older patients with MS had increased neuroaxonal and astroglial injury ...

WEST PALM BEACH, Fla. — Discontinuing disease-modifying therapies (DMTs) for multiple sclerosis (MS) after prolonged disease stability poses minimal risk for patients aged > 60 years, highlighting the ...